Reviews Ilaris


No reviews yet.

Ilaris Drug Description
ILARIS
(canakinumab) Injection for Subcutaneous use
DRUG DESCRIPTION



What are the possible side effects of canakinumab (Ilaris)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:

signs of infection such as fever, chills, sore throat, flu symptoms, easy bruising or bleeding (nosebleeds, bleeding gums), loss of appetite, nausea and vomiting, mouth sores, unusual weakness;
cough with yellow or green mucus;
stabbing chest...
Read All Potential Side Effects for Ilaris »




Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/K isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298).
The biological activity of canakinumab is measured by comparing its inhibition of IL-1β-dependent expression of the reporter gene luciferase to that of a canakinumab internal reference standard, using a stably transfected cell line.
ILARIS is supplied in a sterile, single-use, colorless, 6mL glass vial with coated stopper and aluminum flip-off cap. Each vial contains 180 mg of canakinumab as a white, preservative-free, lyophilized powder. Reconstitution with 1 mL of preservative-free Sterile Water for Injection is required prior to subcutaneous administration of the drug. The reconstituted canakinumab is a 150 mg/mL solution essentially free of particulates, clear to slightly opalescent, and is colorless or may have a slightly brownish-yellow tint. A volume of up to 1 mL can be withdrawn for delivery of 150mg/mL canakinumab for subcutaneous administration. Each reconstituted vial contains 180 mg canakinumab, sucrose, L-histidine, L-histidine HCL monohydrate, polysorbate 80 and Sterile Water for Injection. No preservatives are present.
Last reviewed on RxList: 7/20/2009




Ilaris Drug Description
ILARIS
(canakinumab) Injection for Subcutaneous use
DRUG DESCRIPTION



What are the possible side effects of canakinumab (Ilaris)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:

signs of infection such as fever, chills, sore throat, flu symptoms, easy bruising or bleeding (nosebleeds, bleeding gums), loss of appetite, nausea and vomiting, mouth sores, unusual weakness;
cough with yellow or green mucus;
stabbing chest...
Read All Potential Side Effects for Ilaris »




Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/K isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298).
The biological activity of canakinumab is measured by comparing its inhibition of IL-1β-dependent expression of the reporter gene luciferase to that of a canakinumab internal reference standard, using a stably transfected cell line.
ILARIS is supplied in a sterile, single-use, colorless, 6mL glass vial with coated stopper and aluminum flip-off cap. Each vial contains 180 mg of canakinumab as a white, preservative-free, lyophilized powder. Reconstitution with 1 mL of preservative-free Sterile Water for Injection is required prior to subcutaneous administration of the drug. The reconstituted canakinumab is a 150 mg/mL solution essentially free of particulates, clear to slightly opalescent, and is colorless or may have a slightly brownish-yellow tint. A volume of up to 1 mL can be withdrawn for delivery of 150mg/mL canakinumab for subcutaneous administration. Each reconstituted vial contains 180 mg canakinumab, sucrose, L-histidine, L-histidine HCL monohydrate, polysorbate 80 and Sterile Water for Injection. No preservatives are present.
Last reviewed on RxList: 7/20/2009




Ilaris Drug Description
ILARIS
(canakinumab) Injection for Subcutaneous use
DRUG DESCRIPTION



What are the possible side effects of canakinumab (Ilaris)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:

signs of infection such as fever, chills, sore throat, flu symptoms, easy bruising or bleeding (nosebleeds, bleeding gums), loss of appetite, nausea and vomiting, mouth sores, unusual weakness;
cough with yellow or green mucus;
stabbing chest...
Read All Potential Side Effects for Ilaris »




Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/K isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298).
The biological activity of canakinumab is measured by comparing its inhibition of IL-1β-dependent expression of the reporter gene luciferase to that of a canakinumab internal reference standard, using a stably transfected cell line.
ILARIS is supplied in a sterile, single-use, colorless, 6mL glass vial with coated stopper and aluminum flip-off cap. Each vial contains 180 mg of canakinumab as a white, preservative-free, lyophilized powder. Reconstitution with 1 mL of preservative-free Sterile Water for Injection is required prior to subcutaneous administration of the drug. The reconstituted canakinumab is a 150 mg/mL solution essentially free of particulates, clear to slightly opalescent, and is colorless or may have a slightly brownish-yellow tint. A volume of up to 1 mL can be withdrawn for delivery of 150mg/mL canakinumab for subcutaneous administration. Each reconstituted vial contains 180 mg canakinumab, sucrose, L-histidine, L-histidine HCL monohydrate, polysorbate 80 and Sterile Water for Injection. No preservatives are present.
Last reviewed on RxList: 7/20/2009




Ilaris Drug Description
ILARIS
(canakinumab) Injection for Subcutaneous use
DRUG DESCRIPTION



What are the possible side effects of canakinumab (Ilaris)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:

signs of infection such as fever, chills, sore throat, flu symptoms, easy bruising or bleeding (nosebleeds, bleeding gums), loss of appetite, nausea and vomiting, mouth sores, unusual weakness;
cough with yellow or green mucus;
stabbing chest...
Read All Potential Side Effects for Ilaris »




Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/K isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298).
The biological activity of canakinumab is measured by comparing its inhibition of IL-1β-dependent expression of the reporter gene luciferase to that of a canakinumab internal reference standard, using a stably transfected cell line.
ILARIS is supplied in a sterile, single-use, colorless, 6mL glass vial with coated stopper and aluminum flip-off cap. Each vial contains 180 mg of canakinumab as a white, preservative-free, lyophilized powder. Reconstitution with 1 mL of preservative-free Sterile Water for Injection is required prior to subcutaneous administration of the drug. The reconstituted canakinumab is a 150 mg/mL solution essentially free of particulates, clear to slightly opalescent, and is colorless or may have a slightly brownish-yellow tint. A volume of up to 1 mL can be withdrawn for delivery of 150mg/mL canakinumab for subcutaneous administration. Each reconstituted vial contains 180 mg canakinumab, sucrose, L-histidine, L-histidine HCL monohydrate, polysorbate 80 and Sterile Water for Injection. No preservatives are present.
Last reviewed on RxList: 7/20/2009




Ilaris Drug Description
ILARIS
(canakinumab) Injection for Subcutaneous use
DRUG DESCRIPTION



What are the possible side effects of canakinumab (Ilaris)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:

signs of infection such as fever, chills, sore throat, flu symptoms, easy bruising or bleeding (nosebleeds, bleeding gums), loss of appetite, nausea and vomiting, mouth sores, unusual weakness;
cough with yellow or green mucus;
stabbing chest...
Read All Potential Side Effects for Ilaris »




Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/K isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298).
The biological activity of canakinumab is measured by comparing its inhibition of IL-1β-dependent expression of the reporter gene luciferase to that of a canakinumab internal reference standard, using a stably transfected cell line.
ILARIS is supplied in a sterile, single-use, colorless, 6mL glass vial with coated stopper and aluminum flip-off cap. Each vial contains 180 mg of canakinumab as a white, preservative-free, lyophilized powder. Reconstitution with 1 mL of preservative-free Sterile Water for Injection is required prior to subcutaneous administration of the drug. The reconstituted canakinumab is a 150 mg/mL solution essentially free of particulates, clear to slightly opalescent, and is colorless or may have a slightly brownish-yellow tint. A volume of up to 1 mL can be withdrawn for delivery of 150mg/mL canakinumab for subcutaneous administration. Each reconstituted vial contains 180 mg canakinumab, sucrose, L-histidine, L-histidine HCL monohydrate, polysorbate 80 and Sterile Water for Injection. No preservatives are present.
Last reviewed on RxList: 7/20/2009





Other reviews about Ilaris on wordpress

Phil Ivey beats Ziigmund - wins $555.000
  by Admin
Lately we have seen Ilari "Ziigmund" Sahamies beating Phil Ivey every time they play - but this time was different. Phil Ivey accepted Ilaris challenge to play […]


Research Progress for Autoimmune Disorders
  by altaloman
Ilaris Marks New Drug Development Approach for Novartis | Newly approved Ilaris treats an extremely rare group of autoimmune diseases. The drug's existence is due to the persistence […]


FOURTH SUNDAY AFTER PENTECOST COMMEMORATION OF ALL THE SAINTS OF RUS’-UKRAINE JUNE 28, 2009
  by sspeterandpaulucc
Saturday, June 27 4:00 PM Demetri and Anna Carpa – Charles Drazba […]


Bristol-Myers Squibb to Acquire Medarex
  by prnews
Bristol-Myers Squibb Company and Medarex, Inc. announced that the companies have signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per […]


Novartis posts 1 percent growth in 3Q net profit
  by lenschic
Step back Novartis had a 1% growth in profit. I guess in today's market if your not Essilor, that's actually not to bad. Drug maker Novartis AG posted a […]


2009 FDA drug approvals
  by nanoresearchnews
2009 FDA drug approvals Bethan Hughes In a year in which regulators and drug companies gained familiarity with risk management strategies, the number of new drug approvals was similar to […]


On innovation
  by goodmusicidance
Wise and inspiring innovative thinking from the Swiss pharma Novartis, #8 most innovative company 2010 (source: Fast Company) Since focusing its R&D on rare diseases and biotech, including vaccines […]


Novartis - Business
  by El Horror
About - Novartis = Merger of Ciba-Geigy Ltd. and Sandoz Laboratories in 1996. - Ciba-Geigy = Merger of J. R. Geigy Ltd. and Ciba in 1970. - Revenues: $53 billion in […]



Other reviews about Ilaris on web:

For U.S. residents Only. Ilaris - Splash Page


Ilaris (canakinumab) is used to treat rare genetic conditions such as Familial Cold Autoinflammatory Syndrome. Includes Ilaris side effects, interactions and indications. Ilaris Information from Drugs.com


Basel, June 18, 2009 - The US Food and Drug Administration (FDA) has approved Ilaris® (canakinumab) for the treatment of children and adults with cryopyrin-associated periodic ... New biological therapy Ilaris® approved in US to treat children ...


Learn about the prescription medication Ilaris (Canakinumab Injection), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Ilaris (Canakinumab Injection) Drug Information: Uses, Side ...


All about Ilaris. View complete and up to date Ilaris information - part of the Drugs.com trusted medication database. Ilaris Facts and Comparisons at Drugs.com


Upending the usual model of drug development, Novartis finds that focusing on a rare disease with well-understood genetics can pay off big time. The FDA O.K.'s Novartis' Ilaris - BusinessWeek


HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ILARIS safely and effectively. See full prescribing information for ILARIS ... HIGHLIGHTS OF PRESCRIBING INFORMATION


Canakinumab (INN, trade name Ilaris, previously ACZ885) is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the ... Canakinumab - Wikipedia, the free encyclopedia


Information on the Novartis prescription medicine Clozaril. ... For more information and product details, visit the Ilaris brand website: Ilaris (canakinumab) - Novartis Pharmaceuticals





Featured Reviews

Reviews Sodium Sulfacetamide Lotion

Klaron Drug Description KLARON® (sodium sulfacetamide lotion) Lotion, 10% DRUG DESCRIPTION What are the possible side effects of sodium sulfacetamide topical (Klaron, Sebizon)? Serious side effects are not likely to occur with...
Read More  |  Review This
Reviews Orencia

Orencia Drug Description ORENCIA (abatacept) Lyophilized Powder for Intravenous Infusion DRUG DESCRIPTION What are the possible side effects of abatacept (Orencia)? Some people receiving an abatacept injection have had a reaction...
Read More  |  Review This
Reviews Afinitor

Afinitor Drug Description AFINITOR (everolimus) Tablets for Oral Administration DRUG DESCRIPTION What are the possible side effects of everolimus (Afinitor)? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Reviews Ritalin LA

Ritalin LA Drug Description Ritalin LA® (methylphenidate hydrochloride) Extended-Release Capsules DRUG DESCRIPTION What are the possible side effects of methylphenidate? Get emergency medical help if you have any of these...
Read More  |  Review This
Reviews Mephobarbital

Mebaral Drug Description MEBARAL® (mephobarbital) Tablets, USP DRUG DESCRIPTION What are the possible side effects of mephobarbital (Mebaral)? Get emergency medical help if you have any of these signs of an allergic reaction:...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....